Neoadjuvant chemotherapy with P-ELF ( @entity900 , @entity2879 , @entity4181 , @entity1487 ) followed by radical resection in @entity1 with initially unresectable XXXX : a phase II study.

@entity4181 @entity1 @entity137 @entity5 @entity900 @entity2879 @entity1398 @entity1820 @entity3 @entity356 @entity1487
BACKGROUND: @entity356 is the most frequent @entity1820 in Mexico. Only 33% of cases are resectable. Our aim was to determine the activity and @entity137 of the @entity900 , @entity2879 , @entity4181 , and @entity1487 combination in initially unresectable @entity5 and to determine its ability to permit resection. METHODS: Sixty @entity1 with unresectable @entity356 were treated with @entity900 80 mg/m2, @entity2879 80 mg/m2, @entity4181 25 mg/m2, and @entity1487 800 mg/m2 by central intravenous catheter for 4 consecutive days. Two courses of this combination were followed by surgical resection. RESULTS: The overall response rate was 36.8% (20 partial responses and one complete response). By using logistic regression analysis, the @entity5 , node, and @entity3 stage (risk ratio, 2.04; 95% confidence interval, 1.03-4.02; P = .039) was identified as the response determinant to chemotherapy. Major @entity137 was grade 3 or 4 @entity1398 in 67% of @entity1 . Ten resections were performed (17.5%); five were curative and five palliative. Operative morbidity and mortality rates were 40% and 10%, respectively. The median length of survival was 7.46 and 13.3 months for nonresponders and responders, respectively (P = .011). CONCLUSIONS: The @entity900 , @entity2879 , @entity4181 , and @entity1487 combination is active in advanced @entity356 and the @entity137 level is acceptable. This treatment permits a 17.5% resection rate in previously unresectable @entity5 . A randomized trial of surgery vs. neoadjuvant chemotherapy plus surgery is warranted.
